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Nuclear Receptors in Sicily: Meeting Review
All in the Famiglia
Thomas Perlmann* and Ronald M. Evans² into a repressive chromatin structure that restricts the
accessibility of the template to the basal transcription*Ludwig Institute for Cancer Research
S171 77 Stockholm machinery. Thus, as suggested by Beato, and supported
by experiments reported by OÈ . Wrange (Karolinska Insti-Sweden
²Howard Hughes Medical Institute tute) using in vitro±reconstituted nucleosomes, the role
of the glucocorticoid receptor is to function, at leastThe Salk Institute for Biological Studies
La Jolla, California 92037 in part, to counteract chromatin-mediated repression.
As discussed by L. Krause (UCSD) and J. Kadonaga
(UCSD), the ``ground'' state or default status of an en-
dogenous target gene would be transcriptionally inac-The EMBO workshop on the structure and function of
tive. The role of a transcription factor would be to initiallynuclear receptors (NRs) was held May 2±5, 1997, in the
counteract the chromatin effect leading to a dere-majestic and ancient city of Erice, Sicily. Erice sits high
pressed template. This, in turn, would be followed by aabove a coastal mountaintop offering a commanding
``true activation'' event equivalent to robust transcrip-view of the Mediterranean and the dramatic Sicilian
tional initiation. Kadonaga described dissection of thiscountryside. The fortification walls of the city stem back
putative multistep process by creating chromatin tem-to more than 700 B.C. and speak of a strategic site
plates to directly assess the action of NRs in an in vitro±that has been invaded dozens of times throughout the
reconstituted system. While previous in vitro transcrip-tumultuous European history from the Phoenicians, to
tion studies have been described, this is the first withthe Greeks, Romans, Vandals, Ostrogoths, Moors and
chromatin-based templates. The effects with the estro-Normans, to name a few. During the week it was invaded
gen receptor (ER) are clear and dramatic. Fifteen- toby the NR field in which the intellectual battles were
fifty-fold inductions were seen, all in a hormone-depen-pitched on a projection screen in the Ettore Majorana
dent fashion. The estrogen receptor can be added eitherchapel.
before or after chromatin assembly, and the entire pro-
cess was shown to be dependent on the known activa-Chromatin-Protecting Armor
tion domains in the ER. The improved regulation appearsNRs function as molecular machines to transduce a
to be a consequence of chromatin suppressing basalhormonal signal into a transcriptional response. As se-
activity of the promoter thus increasing the fold of induc-quence-specific DNA binding proteins, the action of the
tion. Interestingly, estrogen antagonists failed to acti-receptor primarily occurs at the site of the target gene.
vate although these complexes can be bound to theQuiescent genes could be viewed as being wrapped
template. Continuing in this vein, A. Wolffe (NICHD) de-in a protective chromatin shield to fend off centroviral
scribed the use of replication-dependent chromatin as-advances from an errant RNA polymerase. Dramatic ef-
sembly to identify three regulatory steps in the regula-fects of hormones on chromatin structure have long
tion of transcription by the thyroid hormone receptorbeen recognized; whether this was causal to the tran-
(TR). These three steps include: (1) the establishmentscriptional response or merely its consequence was un-
of a repressive chromatin structure; (2) disruption of theclear. In addition, how such changes in chromatin struc-
chromatin template; and (3) transcriptional activation.ture were directed by receptors was simply unknown.
As is apparent, this is similar to the events describedOne popular model is that mere binding by receptor was
by Kadonaga and Beato although with a completelysufficient to initiate a change in chromatin by altering
different regulatory system. In this approach, clonednucleosome position. In contrast, the effort to identify
templates are microinjected into the Xenopus oocytethe biochemical basis for transcriptional regulation has
nucleus, which are then assembled in a natural chroma-led in recent years to theconsideration that NR cofactors
tin structure. In this way, Wolffe has been able toaddressmight serve as active mediators of the regulatory effect.
one of the more vexing problems in NR transcription byFrom the view of an insider, it has often seemed that
demonstrating that nonliganded RXR:TR heterodimersthose labs studying chromatin remodeling and those
can not only bind to chromatin but also may facilitatestudying NR cofactors appeared to be on opposite sides
the formation of a repressive chromatin structure. Con-of the arena taking unrelated approaches to an other-
clusions that arise out of this important model systemwise common quest. However, in the last year, these
include the demonstration that the nonliganded TR:RXRtwo fields, like lost allies, have been reintroduced to
heterodimers bind to nucleosome DNA, make use ofeach other and are enjoying a new-found synergy. M.
chromatin to repress transcription, control nucleosomeBeato (University of Marburg) outlined the general path-
position, and can influence both nucleosome modifica-way by which the MMTV LTR utilizes a chromatin-based
tion and, ultimately, disruption. One caveat that remains,structure to control its transcription. In this case, nucleo-
however, is the accuracy with which the microinjectedsomesare phased in a fashion that allows glucocorticoid
DNAs reflect true physiologic templates.receptor but not other transcription factors to bind to
target DNA. Accordingly, hormone treatment leads to a
rapid alteration in chromatin structure and at the same HATs off to Histones
These studies on chromatin-based transcriptional con-time promotes cooperative binding of other transcrip-
tion factors. Presumably, it is the packaging of DNA trol have come to the frontline in part based on the
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Figure 1. Hormonal Remodeling of Chro-
matin
Figure illustrates shift in cofactor complexes
triggered by hormone binding.
recent discoveries that multiple NR coactivators appear M. Parker (ICRF) described domain mapping studies
that led to the identification of a short NR ``signature''to be directly involved in chromatin remodeling. While
many NR-associated proteins have been identified, the motif sequence present in a variety of coactivators in-
cluding SRC-1, CBP/p300, TIF-1, TIF-2, and other recep-CREB binding protein (CBP) and its homolog p300, the
CBP associated factors P/CAF, and the steroid receptor tor binding proteins. Peptides, including this 10 amino
acid segment, block interactions of SRC-1 with recep-cofactor SRC-1 and its homologs (e.g., TIF2) have re-
ceived considerable attention. R. Evans (HHMI/The Salk tors and mutations in the motif block cofactor binding
both in vivo and in vitro. However, since this motif isInstitute) discussed recent studies that suggest theexis-
tence of putative coactivator and corepressor com- present in thousands of proteins, it alone cannot explain
the properties of these cofactors. How coactivatorsplexes. In the first case, a new SRC-1/TIF2 cofactor
termed activator of retinoid receptors (ACTR) was de- function may not be as simple as their recruitment to
the target template. P. Webb (UCSF) described that fu-scribed that functions as a novel histone acetyltrans-
ferase (HAT). ACTR, in turn, conscripts both CBP and sions of coactivators such as SRC-1 with yeast Gal4
DNA-binding domains are insufficient to allow this pro-P/CAF and these three proteins form a trimeric activa-
tion complex. The link between coactivation and enzy- tein to function at a UAS binding site. However, in the
presence of a cotransfected estrogen receptor (ER)matic activity was established when David Allis first
isolated the histone acetyltransferase from tetrahymena ligand binding domain, agonists (but not antagonists)
will ``trigger'' Gal4-CBP activation. How such triggering(Brownwell et al., 1996), which was shown to be homolo-
gous to the yeast coactivator, GCN-5, and subsequently occurs is not clear. Perhaps the HAT activity is potenti-
ated by association of the ER with CBP or the LBDto human P/CAF (Wang et al. 1997). This was strength-
ened by the discovery that CBP is itself an intrinsic (ligand binding domain) after binding CBP recruits other
factors that can cooperate to promote activation.histone acetylase (Ogryzko et al., 1996; Yang et al.,
1996). Together, these results suggest that at least one Is the role of ligand simply to induce a conformation
resulting in coactivator recruitment and release of core-aspect of transcriptional coactivation involves the re-
cruitment by receptors of a multimeric enzymatic com- pressor? Clearly not in the case of steroid receptors
whose DNA binding is ligand dependent (Beato et al.,plex to the DNA template. Reciprocally, the search for
NR corepressors led to the isolation of the silencing 1995). In the absence of ligand, steroid receptors are
sequestered in a complex including heat shock proteinmediators, termed SMRT, and N-Cor (Chen and Evans,
1995; HoÈ rlein et al., 1995). These proteins interact with 90 (hsp90). Ligand is proposed to dissociate the com-
plex and enable receptor dimerization, nuclear translo-receptors in the absence of hormone and act as tran-
scriptional corepressor for the TR, RAR, and other mem- cation, and DNA binding. As most other receptors are
apparently not associated with hsp90 and are constitu-bers of the family. As described by Evans (and recently
published in Cell and Nature), SMRT/N-Cor form com- tively localized in the cell nucleus, the common view has
been that DNAbinding is usually not a ligand-dependentplexes with the yeast homolog of Sin3 (mSin3A) and
RPD-3 (HDAC-1), a histone deacetylase (Alland et al., process, a conclusion that is largelysupported by invitro
DNA binding experiments. It was therefore somewhat1997; Heinzel et al., 1997; Nagy et al., 1997). This work,
suggests that transcriptional repression is in part medi- surprising when recent in vivo footprinting indicated that
also RAR-RXR heterodimers bound to a specific RAREated by the action of targeted histone deacetylases re-
cruited to promoters by negative regulatory factors. in the RARb gene promoter in a ligand-dependent man-
ner (Dey et al., 1994; Chen et al., 1996). In contrast,According to this view, transcriptional regulation by re-
ceptors would be controlled by selective recruiting of however, H. Stunnenberg (EMBL, Heidelberg) reported
that at least one other receptor, namely the oncogeniccorepressors or coactivators in response to hormone.
This, in turn, would control the balance of enzymatic variant of TRa (v-erbA), can bind in vivo to a newly
identified v-erbA responsive element in the carbonicactivity in a target promoter. If the scenario established
by this model is correct, then histone tails of nucleo- anhydrase II gene. As mutations in v-erbA prevent ligand
binding, this is a clear example of ligand-independentsomes may be sites through which a major signal trans-
duction pathway exerts its regulatory effect. NR DNA binding. Differences may exist between RAR,
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RXR, and TR, or alternatively, in vivo footprinting may fail not seen in GRdim/dim animals, including aberrent differen-
tiation of adrenal chromaffin cells, hyperplasia of thetodetect weak protein±DNA interactions indeacetylated
and less accessible chromatin. In any event, it is clear adrenal cortex, and abnormal lung development. Al-
though residual GRE binding of GRdim can not be entirelythat caution is in place before it is concluded that ligands
are generally required for NR to bind to DNA. ruled out, these results support the essential role of GR
function by mechanisms that may be independent of
classical GRE binding and direct transcriptional acti-
The End Game vation.
Glucocorticoids are ballistic for T cells functioning as Even direct regulation at GRE controlled genes is vari-
potent immunosuppressives and, when administered to ably orchestrated by GR as previously demonstrated
young animals, cause thymic involution by inducing mainly in K. Yamamoto's lab (UCSF). This group has
thymocyte apoptosis. They promote cell death, in part, shown that GR regulation at GREs is dramatically influ-
by inhibiting T cell activation by NF-kB signaling and enced by the DNA binding site itself. Thus, the nature
the AP-1 response pathway. In contrast to this inhibition, of theGRE influences whether GRwill activate or repress
as reported by B. Thompson (University of Texas, Gal- gene transcription. The DBD can functionally interact
veston), they synergize with the protein kinase A path- with the N-terminal activation domain to repress its acti-
way although the basis for this synergism is not clear. vation function (Lefstin et al., 1994). Yamamoto contin-
One clue has come from the study of the expression of ued to present structural data on GR DBD complexes
the c-myc gene. While glucocorticoids and retinoids with GRE derived by NMR spectroscopy showing that
have previously been shown to lead to rapid downregu- binding to a positive GRE induces a conformational shift
lation of c-myc, Thompson reported strong synergism in the DNA binding domain primarily involving the D box
with forskolin resulting in a near complete loss of c-myc region. Interestingly, DBDs from mutated versions of GR
mRNA and protein, presumably functioning as another harboring mutations within the DBD, which previously
block to T cell stimulation. M. Karin (UCSD) described were shown to relieve the inhibitory function, are in the
a potential basis for steroid inhibition of AP-1- and NF- ``active'' conformation even in the absence of DNA as
kB-mediated transcription. NF-kB is activated by proin- determined by NMR. The results emphasize the impor-
flammatory cytokines, of viral and bacterial infections tance of the DNA as a regulatory signal for NRs.
and, interestingly, can protect cells against apoptosis.
Glucocorticoids appear to inhibit NF-kB in part by ele-
vating the expression of IkBa, a specific inhibitor protein Ten Facts about Fat
Orphan receptors provide a continuing source of newreponsible for retaining NF-kB complexes in the cyto-
plasm. Challenging these results, G. Haegeman (Univer- opportunity for discovering new ligands and expanding
our understanding of the complex nature of endocrinesity of Gent, Belgium) suggested that glucocorticoids
may act exclusively in the nucleus to inhibit the trans- physiology. Among the most intensively studied over
the last several years are the peroxosime proliferator-activating capacity of the p65 subunit of NF-kB. Thus,
while cross-regulation between these pathways has activated receptors (PPARs), which are believed to con-
trol the expression of genes involved in lipid homeosta-been well described, the molecular basis for this still
remains controversial. sis. W. Wahli (University of Lausanne) described how
the PPARa isoform activates gene transcription in re-Continuing on the theme of glucorticoid regulation,
H. Reichardt (German Cancer Research Center, Heidel- sponse to a variety of compounds including hypolip-
idemic drugs, as well as natural fatty acids. In contrast,berg) described recent studies on the characterization
of glucocorticoid receptor±targeted gene mutations in B. Spiegelman (Dana-Farber Cancer Institute) reviewed
evidence suggesting the PPARg isoform serves as amice. Repression of AP-1 does not appear to require
classical GRE DNA binding in AP-1 regulated promoters. master factor for adipoctye differentiation. Despite the
plethora of PPAR-activators, it is only recently that PPARThis appears to be the case also for the inhibition of
NF-kB, as a mutation within the GR DBD dimerization ligands have been identified. In a series of recent studies
(see Kliewer et al., 1995, and Forman et al., 1995a), themotif (D box) does not prevent repression although it
effectively blocks GRE binding (S. Okret, Karolinska In- prostaglandin metabolite PGJ2 and the insulin-sensitiz-
ing thiozoladinedione (TZD) drugs are described asstitute). As a consequence, such mutations can distin-
guish between positive regulation through GREs and PPARg ligands. Why activation of PPARg in fat leads to
insulin sensitization in muscle remains an unresolvednegative regulation of AP-1 and NF-kB. Reichardt de-
scribed a gene replacement approach where a mutation but important medical issue. Spiegelman went on to
describe that phosphorylation of PPARg by the MAP-that prevents GRE binding by abolishing dimerization
(here referred to as GRdim) was targeted to the GR locus kinase pathway appears to block adipocyte differentia-
tion. Hence, this cross-regulation may represent a veryin mice. Since GRdim is as effective as wild-type GR in
blocking AP-1, the experiment selectively investigates important control mechanism that impacts on adipocyte
differentiation as well as insulin sensitivity. The abilitythe in vivo contribution of the GRE-dependent functions
of GR. Interestingly, in contrast to the previously de- of PPARg to induce terminal adipogenesis raises the
possibility that ligand stimulation of this receptor couldscribed early perinatal lethality of GR2/2 mice (Cole et
al., 1995), the GRdim/dim mice are viable, indicating that be beneficial in the treatment of malignancies where the
receptor is expressed. Indeed, Spiegelman provided anthe GRE binding function of GR is less essential than
had previously been expected. Remarkably, several of exciting description of recent experiments demonstra-
ting the expression of PPARg in liposarcomas, breastthe phenotypes previously observed in GR2/2 mice were
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and colon cancer, and the potential of g activators to cells. This indicates that RARa and RARg require hetero-
dimerization with RXRa, a conclusion that is further sup-dramatically slow cell growth in vitro. Walter Wahli de-
scribed how a variety of eicosanoids and fatty acids ported from gene targeting experiments in mice (see
below). Third, and perhaps most striking, targeting itselfmay function as PPARa ligands, which leads to the un-
usual and important conclusion that some NRs may can induce functional redundancy. Accordingly, when
using synthetic RAR isotype±specific ligands, RARg wasinteract physiologically with a variety of natural ligands.
Furthermore, some of these natural ligands consist of shown to be ineffective in inducing differentiation of
F9 cells into parietal endoderm. In contrast, an RARg-common dietary nutrients as opposed to classic hor-
mones. This provides a direct link between nutrition and specific ligand was able to induce differentiation in
RARg2/2 cells demonstrating that RARg now had ac-physiologic homeostasis.
This problem was further addressed by M. Milburn quired an active role in the targeted cells (Taneja et al.,
1996). This is an important lesson considering the many(Glaxo Wellcome, Inc.) who presented one of the three
crystallographic talks at the meeting. Milburn specifi- phenotypes of knock-out mice with mild or no pheno-
types. The possibility of a similar genetic ``adaptation''cally described the crystal structure of PPARg in both
the presence and absence of cognate ligands. The li- in the absence of a particular gene product may have
to be considered as a possible explanation for manygand used was one of the TZDs, which bind to PPARg
with high affinity. In support of the conclusion that observations. Finally, rescue experiments have proven
very useful in this system and have defined specificPPARs are designed to interact with a variety of ligands,
Milburn reported that the ligand binding pocket of roles for distinct functional domains, such as the RARg
N-terminal AF1 domain. Furthermore, a protein kinasePPARg is unusually large (1300 AÊ 3) and only 40% of this
space is filled by the TZD ligand in the PPARg structure. A phosphorylation site in RARa was shown to be selec-
tively required for parietal endoderm differentiationThis clearly indicates that TZD binding only represents
one out of several possibilities for ligand binding. In while the corresponding site in RARg is not required.
The results emphasize the role of retinoid receptors ascontrast, J. Baxter (UCSF) and Dino Moras (IGBMC,
France) described the previously published TRa- and integrators of multiple signals and stimuli.
Chambon continued to report on the impressiveRARg-structures in which ligands are very tightly fitted
in their respective ligand binding pockets (Renaud et amount of data that has now been accumulated on phe-
notypes in retinoid receptor knock-out mice, includingal., 1995; Wagner et al., 1995). It is therefore noteworthy
that RAR can also bind two structurally distinct ligands compound knock-outs with targeted mutations in more
than one retinoid receptor gene. Many of the deficien-with high affinity, namely all-trans retinoic acid (atRA)
and 9-cis RA (9cRA). Moras reported new data on the cies have previously been defined in fetuses from vita-
min A±deficient (VAD) dams. While mutations of individ-9cRA-bound RARg hence allowing comparison of how
the two ligands are associated with the RARg LBD. In ual genes have been shown to result in surprisingly mild
phenotypes, most VAD phenotypes are observed in vari-contrast to the liganded PPARg, both atRA and 9cRA
are tightly fitted into the ligand binding pocket of RAR ous combinations of retinoid receptor knock-outs (Kast-
ner et al., 1995). Furthermore, the results clearly indicatewith every atom of the ligands in direct contact with one
or more proximal residues. Interestingly, although atRA that RAR/RXR heterodimeric complexes are responsible
for vitamin A signaling in vivo (Kastner et al., 1997).and 9cRA are structurally distinct, when bound, both
molecules are distorted by the pocket toward strikingly Specifically, RXRa appears to be the main heterodimer-
ization partner of RARs during embryogenesis. Whilesimilar formations. Thus, both receptor and ligand exert
reciprocal conformational changes on each other. the function of RXR as an auxiliary partner of many
receptors is indicated by the severity of the phenotype
observed in RXRa2/2, RXRb2/2 double mutant mice,The RAR and TR Genetic Battlefield
As a reflection of their important regulatory roles during which die around embryonic day 10, it is striking that
animals lacking 5 out of 6 RXR alleles, having only adevelopment, retinoids are also potent regulators of
complex differentiation events in vitro. For example, single allele of RXRa, are viable, a quite remarkable
demonstration of redundancy (Krezel et al., 1996).treatment of F9 embryonic carcinoma cells with varying
concentrations of RA results in controlled induction of RXR is not only a retinoid receptor which can bind
9-cis RA,but can also function as anunliganded auxiliaryprimitive, parietal, or visceral endoderm after exposure
to RA. While knock-out experiments are usually per- protein required for high affinity DNA binding of many
NRs including RAR (Mangelsdorf et al., 1995). That thisformed in whole animals, P. Chambon (IGBMC, Stras-
bourg) reported on recent gene targeting experiments is an essential function for RXR is clearly demonstrated
by many previous experiments including the strong ge-of RARa, RARg, and RXRa in F9 cells (Taneja et al.,
1996; Chiba et al., 1997). Some of the most striking netic evidence presented above. Paradoxically, how-
ever, the role of RXR as a classical signaling receptorconclusions can be enumerated. First, despite the func-
tional similarity of RAR isotypes in vitro and in in vivo has remained less clear. The Chambon lab has
now addressed this issue in an experiment utilizing atransfected cells, RARa and RARg mutant cells have
distinct effects on F9 cell differentiation. Thus, RARa gene replacement strategy in mice. In these animals,
RXRa has been manipulated so that a mutation (referredtargeted cells were defective in the formation of parietal
endoderm and visceral endoderm differentiation was toas RXRao) inactivatedthe ligand-dependent transacti-
vation domain AF2 of RXR while sparing the ability todelayed. On the other hand, RARg is required for both
primitive and parietal but not visceral endoderm. Sec- form heterodimers. These animals are not as severely
affected as RXRa2/2 mice but do display some of theond, RXRa affects all of the studied processes in F9
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RXRa2/2 phenotypes with variable penetrance. In addi- either the TRa1 or TRa2 isoforms has illuminated the in
tion, other abnormalities normally seen in RAR mutant vivo role of each of the isoforms as presented by B.
mice were detected, particularly when RXRao was com- Vennstrom (Karolinska Institute). While the TRa1 mutant
bined with single targeted RAR isotypes. This led to the mice show decreased heart rate and body temperature,
conclusion that liganded RXR apparently plays a role as well as a mild hypothyroidism, TRa2 does not display
in retinoid signaling, not only as a heterodimerization any dramatic phenotype. Neither TRa1 or TRa2 affects
partner, butalso as a ligand-activated receptor. Presum- survival of the animals, and the mice are fertile. The
ably the ligand would be identical to 9cRA or an as-yet- phenotype of the TRa1 animals is distinct from pre-
unidentified RXR ligand. Although other explanations viously describedTRb null mutant mice ascribing unique
for these interesting results can not be entirely ruled functions for the two TR genes (Forrest et al., 1996).
outÐe.g., that the RXRao mutation affects the ability of Although these data would argue that the TRa2 isoform
the RAR partner to function optimally, these results are does not play a significant role in vivo, a new study from
intriguing because they provide the most compelling J. Samarut (CNRS) providesa somewhatsurprising twist
evidence so far for a role of liganded RXR in vivo. to the TR story. Accordingly, a TRa null mutation, which
While it has been presumed that all retinoid receptors inactivates both TRa1 and TRa2 isoforms, generates a
have been identified, D. Moore (Massachusetts General much more severe phenotype than would be expected
Hospital) rattled a provocative sabre at this thesis. The from looking at the relatively mild phenotypes resulting
battlefield was defined by the farnesoid X receptor from mutating either TRa1 or TRa2. TRa null mice are
(FXR), which had previously been shown to form a severely growth retarded beginning 1±2 weeks after
heterodimer with RXR and to respond positively to both birth and die between 3±5 weeks. Defects include aber-
juvenile hormone (JH III) and farnesoic acid (Forman et rent ossification and severely reduced thyroid hormone
al., 1995b). Moore now provides evidence that a potent levels. Interestingly, about half of the homozygous ani-
synthetic retinoid, tetramethyl-tetrahydro-naphthalenyl- mals could be rescued by administration of thyroid hor-
propenyl-benzoic acid (TTNPB) is able to activate the mone. Thus, while TR downregulates hormone levels,
FXR:RXR heterodimer. Since TTNPB is an extremely as demonstrated previously, these results indicate that
potent RAR agonist, the thrust of Moore's argument is TRa plays a key role for thyroid hormone production.
that perhaps FXR is a new retinoic acid receptor. While Importantly, the results raise new questions regarding
direct binding was not established and the activation is
the role of the nonliganded TRa2.
approximately 1000-fold less efficient than RAR activa-
tion, the results remain provocative as they establish Orphan ReceptorsÐCoup d'Etat
that a common synthetic ligand is able to activate two
Orphan NRs constitute the majority of the members of
markedly distinct receptors. Nonetheless, these results
the NR superfamily. Lacking identified ligands, the func-
raise the issue as to the nature of the endogenous FXR
tions of these proteins are often rather obscure and theligand and whether or not FXR responds, as suggested
available information is often limited to what can beby Moore, to a new vitamin A metabolite and whether
assayed in transfected cells and in in vitro experiments.its mutation will explain some features of vitamin A defi-
Gene targeting of orphan receptors can therefore beciency.
unusually rewarding, as the results have the potentialIn addition to its role in normal physiology, the retinoic
of establishing a physiological basis for continuing anal-acid receptor can be mutated to an oncogenic form as
ysis of these proteins. Two of the earliest orphans to bein acute promyelocytic leukemia (APL), which is associ-
identified are the two COUPs, TFI and -II (Qiu et al.,ated with the t(15;17) translocation by fusion of the PML
1996). These receptors have been shown to efficientlyand RAR genes. Expression of the resulting PML/RARa
repress activation by several other NRs including RAR,fusion gene in transgenic mice results in a disease ex-
TR, and PPAR. COUP is also one of the most evolution-tremely similar to the human one, demonstrating that
arily conserved receptors and has a well-characterizedformation of the chimeric protein is the molecular basis
counterpart in Drosophila (Sevenup). Homologs haveof this malignancy (Brown et al., 1997). As discussed by
also been cloned from early metazoans including HydraH. de The (CNRS), APL is a unique model system in
(V. Laudet, CNRS). Remarkably, Laudet reported a strik-cancer biology as retinoic acid, which binds the PML/
ing conservation also at the functional level as sug-RARa fusion, leads to clinical remission by inducing
gested by the observation that the Hydra COUP homo-differentiation. Despite the effectiveness of this therapy,
log is expressed in neurons, themajor COUP-expressingpatients can become RA-resistant and relapse. The use
cell type also in vertebrates.of Chinese herbal medicine in the treatment of APL led
S. Tsai (Baylor College of Medicine, Texas) presentedto the recent discovery that arsenic trioxide (As) is a
interesting data showing that COUPs are indeed keydramatic chemotherapeutic agent. Unlike RA, this new
regulators during neuronal development. COUP TFIdrug appears to target the PML moiety of the fusion
gene targeted mice die soon after birth and display defi-protein to promote its degradation, resulting in apo-
ciencies in the formation of cranial nerves IX and X.ptosis and dramatic clinical remission.
These mice also show reduced axonal arborization inAnother of the classical NR ligands is thyroid hormone
the cervical plexus region. Furthermore, the early char-whose receptors come in two flavors, TRa and TRb. In
acterization of the COUP TFII2/2 mice reveals an earlyaddition, several isoforms exist as a result of alternative
embryonic lethal phenotype involving aberrent vascu-splicing. In case of TRa, one isoform binds ligand (TRa1)
larization. Interestingly, COUP TFII expression in thespi-while a second (TRa2) lacks ligand binding ability and
nal cord is apparently regulated by another evolution-has been suggested to downregulate hormone-acti-
vated TRa1. Gene targeting that selectively abolished arily conserved regulatory protein, sonic hedgehog (shh)
Cell
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(S. Tsai). Data identifying an shh-responsive element in partially distinct, the two receptors are colocalized in
several tissues. Therefore, as reported in several talks,the COUP TFII promoter define this gene as one of the
first identified target genes for shh signaling in the devel- it is notable that ERa and ERb form heterodimers that
can be activated by hormone (M. Parker, E. Enmark,oping central nervous system, a tissue where shh is a
key regulator of cell fate specification. and V. Giguere, McGill University). Hence, such hetero-
dimers constitute a novel estrogen-dependent mecha-An important feature of ligands for nucelar receptors
is that they are small lipophilic molecules and hence nism for gene regulation in addition to regulation by ERa
and ERb homodimers. While several groups reportedparticularly useful as pharmaceuticals. As orphan recep-
tors have yet to find their ligands, their potential as that ERa and ERb respond in a similar way to a variety
of tested compounds,differences do exist. For example,targets for drug development remains to be elucidated.
However, the following phenotypes resulting from or- Giguere showed that 4-hydroxy tamoxifene is a partial
agonist for ERa but fails to activate ERb, while anotherphan receptor gene inactivation illustrate some exciting
possibilities in disorders as diverse as neurodegenera- estrogen, Raloxifene, is a more potent antagonist of ERb
than ERa. These and other pharmacological differencestive disease and atherosclerosis. First, T. Perlmann
(Ludwig Institute/Karolinska Institute) reported on a tar- between ERa and ERb may establish a basis for further
therapeutic developments of estrogens in the treatmentgeted mutation of Nurr1, a close relative of NGFI-B/
Nur77 and Nor1/MINOR, resulting in early postnatal of various disorders including breast cancer and osteo-
porosis.death and complete agenesis of midbrain dopamine
cells (ZetterstroÈm et al., 1997). These neurons are the Cross-talk between different signaling pathways con-
verging on transcription factors is common, and ER iscells that degenerate in patients with Parkinson's dis-
ease. Moreover, heterozygous, otherwise healthy mice not an exception in this respect. Thus, ERa can be acti-
vated by several nonligand pathways including thoseshowed decreased levels of dopamine, indicating that
Nurr1 may play a role also in mature dopamine cells triggered by epidermal growth factor and dopamine.
Mutations affecting such regulation have been definedto maintain wild-type levels of the neurotransmitter. In
addition to Parkinson's disease, the results have impli- including a tyrosine residue preceding helix 12 in the
AF2 core (M. Parkerand B. Katzenellenbogen, Universitycations for other dopamine-related disorders such as
schizophrenia and drug abuse. of Illinois, Urbana). This tyrosine is a target for phoshory-
lation in vivo. Its regulatory role is illustrated by muta-Second, nature itself has helped to provide genetic
information on yet another orphan receptor, ROR, which tions that transform ERa into a constitutively active re-
ceptor also in the absence of estrogens. Continuing onrecently was shown to be mutated in ``staggerer'' (sg/
sg) mice (Hamilton et al., 1996). These animals have the theme of constitutively active receptors, but diverg-
ing from ER to yet another orphan receptor, F. Wiebelbeen extensively studied because of their deficiencies
of cerebellar development. An additional function for (Karolinska Institute) reported on data involving OR-
1/UR, a close relative of LXR/RLD-1. Coexpression ofROR has now been defined by the study of sg/sg mice
which were found to suffer from increased sucseptibility GAL4-fused OR-1 and RXR results in constitutively ac-
tive transcription from a reporter containing GAL4 DNAfor atherosclerosis,presumably due to a decreased level
of apo A-I and apo A-II plasma levels (B. Staels). Further- binding sites, evidently as a result of heterodimerization.
Mutations in the RXR helix 12 did not affect this activitymore, transient transfection experiments defined ROR
as a direct regulator of the apo A-I gene through a spe- while it was completely abolished by the corresponding
mutation in OR1. Furthermore, protease protection ex-cific ROR binding site in the promoter. These results
suggest that ROR may be a promising target for drugs periments suggest that the interaction with RXR is re-
sponsible for inducing an ``active'' conformation ofmodulating lipid metabolism.
OR-1. Thus, RXR in effect acts as a ligand for OR1
leading to its activation.
Assault on Estrogen The activity of other types of receptors, expressed in
Considering the continual interest in estrogen receptor neurons of meeting participants, was eventually si-
(ER) function over the years, the word ``renaissance'' lenced at the final hour of an intense meeting. As the
would perhaps be an exaggeration when describing the weary troops disembarked, Erice was once again re-
burst of data reported on ER at this meeting. However, turned to its much deserved majesty and tranquility.
an increased interest level is quite evident, not the least At the nearby Palermo airport, however, an air traffic
stimulated by the recent and quite unexpected identifi- controller strike revealed that no individual is truly im-
cation of a second estrogen binding receptor (ERb) mune from another's sorrow. However, despite the de-
(Kuiper et al., 1996). This receptor was originally cloned lays and frustration, the feeling was that much had been
from a rat prostate cDNA library and sites of ERb expres- accomplished and that the field of nuclear receptors
sion include the prostate, bone, ovary, bladder, lungs, continues to march at a remarkable pace.
and brain. Several groups reported new data on this
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